To the Editor: I have a number of concerns about the study by Dr Malenka and colleagues1 on outcomes following stenting in the bare-metal stent era vs drug-eluting stent era, which concluded that there was a decline in the need for repeat revascularization procedures. First, the authors excluded patients with any percutaneous coronary intervention (PCI) or coronary artery bypass within 1 year. These patients were likely to have bare-metal stents since the drug-eluting stent cohort was from the years immediately after these stents were introduced. Thus, some cases with restenosis within a year were likely to have been left out.
Second, the authors did not perform separate analyses for patients receiving bare-metal vs drug-eluting stents even though this information was available based on codes from the International Classification of Diseases, Ninth Revision, Clinical Modification. Third, no information was provided about the reasons certain patients received bare-metal vs drug-eluting stents, which could have led to a selection bias. There was no analysis of differences between patients in each group. It seems likely that patients who had poorer prognosis or contraindications to dual antiplatelet agents preferentially received bare-metal stents. There may also have been a bias induced by physician preferences or hospital policy.
Fourth, there is a limited follow-up of only 2 years; this may cover most stent thrombosis but not capture restenosis, which is a more chronic process.2 In addition, the study interpretation is limited by the absence of angiographic data about the site of a recurrent event, so it is uncertain whether a recurrent event was restenosis, thrombosis, or an unrelated event in another vessel. Fifth, patients with drug-eluting stents were using clopidogrel, which itself may lower risk of recurrent myocardial infarction and hence may be a confounder.3
Financial Disclosures: None reported.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.